Cargando…
A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
A 51-year-old, male, non-smoker with a 3.4 cm mass in the right middle lobe was diagnosed with large cell neuroendocrine carcinoma (LCNEC). Fluorescence in situ hybridization revealed anaplastic lymphoma kinase (ALK) gene translocation, in agreement with the immunohistochemistry result obtained with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985782/ https://www.ncbi.nlm.nih.gov/pubmed/35694701 http://dx.doi.org/10.1093/pcmedi/pbz005 |
_version_ | 1784682418892963840 |
---|---|
author | Wang, Ye Tian, Panwen Wang, Weiya Li, Yalun Wang, Yu Li, Weimin |
author_facet | Wang, Ye Tian, Panwen Wang, Weiya Li, Yalun Wang, Yu Li, Weimin |
author_sort | Wang, Ye |
collection | PubMed |
description | A 51-year-old, male, non-smoker with a 3.4 cm mass in the right middle lobe was diagnosed with large cell neuroendocrine carcinoma (LCNEC). Fluorescence in situ hybridization revealed anaplastic lymphoma kinase (ALK) gene translocation, in agreement with the immunohistochemistry result obtained with use of ALK-Ventana. Radiographic examinations showed both bone and brain metastasis. After two cycles of chemotherapy consisting of etoposide and cisplatin, the patient achieved stable disease, and was subsequently switched to crizotinib. Both computed tomography and magnetic resonance imaging revealed partial response after 4 months of crizotinib, but progressed after treatment for 10 months, when several hard lymph nodes were palpable in the left supraclavicular fossa. Lymph node biopsy showed similar histology of tumor cells and targeted next-generation sequencing revealed ALK F1174L on exon 23 with two rare forms of ALK rearrangements. This case provides evidence of responsiveness of ALK inhibitors for a rare pattern of ALK-rearranged LCNEC, and suggests that F1174L, a common resistant mutation found in non-small-cell lung cancer, also causes crizotinib resistance in LCNEC. |
format | Online Article Text |
id | pubmed-8985782 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-89857822022-06-10 A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance Wang, Ye Tian, Panwen Wang, Weiya Li, Yalun Wang, Yu Li, Weimin Precis Clin Med Case Report A 51-year-old, male, non-smoker with a 3.4 cm mass in the right middle lobe was diagnosed with large cell neuroendocrine carcinoma (LCNEC). Fluorescence in situ hybridization revealed anaplastic lymphoma kinase (ALK) gene translocation, in agreement with the immunohistochemistry result obtained with use of ALK-Ventana. Radiographic examinations showed both bone and brain metastasis. After two cycles of chemotherapy consisting of etoposide and cisplatin, the patient achieved stable disease, and was subsequently switched to crizotinib. Both computed tomography and magnetic resonance imaging revealed partial response after 4 months of crizotinib, but progressed after treatment for 10 months, when several hard lymph nodes were palpable in the left supraclavicular fossa. Lymph node biopsy showed similar histology of tumor cells and targeted next-generation sequencing revealed ALK F1174L on exon 23 with two rare forms of ALK rearrangements. This case provides evidence of responsiveness of ALK inhibitors for a rare pattern of ALK-rearranged LCNEC, and suggests that F1174L, a common resistant mutation found in non-small-cell lung cancer, also causes crizotinib resistance in LCNEC. Oxford University Press 2019-03 2019-03-15 /pmc/articles/PMC8985782/ /pubmed/35694701 http://dx.doi.org/10.1093/pcmedi/pbz005 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of West China School of Medicine & West China Hospital of Sichuan University. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Report Wang, Ye Tian, Panwen Wang, Weiya Li, Yalun Wang, Yu Li, Weimin A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title | A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title_full | A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title_fullStr | A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title_full_unstemmed | A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title_short | A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance |
title_sort | case of large-cell neuroendocrine carcinoma harboring rare alk fusion with initial response to the alk inhibitor crizotinib and acquired f1174l mutation after resistance |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985782/ https://www.ncbi.nlm.nih.gov/pubmed/35694701 http://dx.doi.org/10.1093/pcmedi/pbz005 |
work_keys_str_mv | AT wangye acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT tianpanwen acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT wangweiya acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT liyalun acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT wangyu acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT liweimin acaseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT wangye caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT tianpanwen caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT wangweiya caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT liyalun caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT wangyu caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance AT liweimin caseoflargecellneuroendocrinecarcinomaharboringrarealkfusionwithinitialresponsetothealkinhibitorcrizotinibandacquiredf1174lmutationafterresistance |